Seroconversion rate after COVID-19 vaccination in patients with solid cancer: A systematic review and meta-analysis.

ABSTRACT: Patients with solid cancer have an increased risk of severe coronavirus disease 2019 (COVID-19) and associated mortality than the general population. This meta-analysis aimed to investigate the currently available evidence about the efficacy of COVID-19 vaccines in patients with solid cancer. We included prospective studies comparing the immunogenicity and efficacy of COVID-19 vaccines between patients with solid cancer and healthy individuals. Relative risks of seroconversion after the first and second dose of a COVID-19 vaccine were separately pooled with the use of random effects meta-analysis. Thirty studies with 11,245 subjects met the inclusion criteria. After first vaccine dose, the pooled RR of seroconversion in patients with solid cancer vs healthy individuals was 0.54 (95%

SUBMITTER: Yin J 

PROVIDER: S-EPMC9746490 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature